Skip to main content
SANA
NASDAQ Life Sciences

Sana Biotechnology Details Q1 Results, Mayo Clinic Investment, and Clinical Progress Amidst Short Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.6
Mkt Cap
$950.046M
52W Low
$1.6
52W High
$6.55
52W Position info
125% above low
Off High info
45% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SANA has more than doubled off its 52-week low of $1.6.

Summary

Sana Biotechnology reported its first-quarter 2026 financial results, detailing a strategic $25 million equity investment from Mayo Clinic and positive clinical progress for its UP421 program, while also highlighting a cash runway into 2027.


Key Events · Financing and Capital Events · SANA

  • Q1 2026 Financials

    Reported a net loss of $47.2 million and a non-GAAP operating cash burn of $37.0 million for Q1 2026.

  • Strategic Equity Investment

    Secured an initial $25.0 million equity investment from Mayo Clinic as part of a collaboration to advance SC451, with an option for an additional $25.0 million.

  • Cash Position & Runway

    Ended Q1 with $101.1 million in cash, with a pro forma cash position of $128.9 million (including the Mayo investment and ATM activity), extending the expected cash runway into 2027.

  • Positive Clinical Data

    Announced positive 14-month follow-up results from a study of UP421 in type 1 diabetes, demonstrating survival and function of transplanted cells without immunosuppression.


Analysis · SANA · Life Sciences

This 8-K furnishes the company's Q1 2026 earnings press release, which provides crucial updates on its financial health and pipeline. While the concurrent 10-Q raised substantial doubt about the company's ability to continue as a going concern, this filing details a strategic $25 million equity investment from Mayo Clinic, which extends the cash runway into 2027. The press release also highlights positive 14-month clinical data for its UP421 program and significant progress towards Phase 1 trials for SC451 and SG293, which are vital for future financing and long-term viability.

At the time of this filing, SANA was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $950M. The 52-week trading range was $1.60 to $6.55. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SANA - Latest Insights

SANA
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.73
Real-time Price: $3.53 info
Change: -$0.2025 (-5%) info
Market Cap: $979.586M info
SANA
Jun 02, 2026, 6:11 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $3.23
Real-time Price: $3.53 info
Change: +$0.2994 (+9%) info
Market Cap: $979.586M info
SANA
May 15, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.07
Real-time Price: $3.53 info
Change: +$0.4575 (+15%) info
Market Cap: $979.586M info
SANA
May 15, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $3.53 info
Change: +$0.5375 (+18%) info
Market Cap: $979.586M info
SANA
May 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.59
Real-time Price: $3.53 info
Change: -$0.0647 (-2%) info
Market Cap: $979.586M info